Pasithea Therapeutics (KTTA)
Clinical-stage developer of an oral MEK inhibitor for NF1-related tumors and advanced cancers.
Something off on this page? Send us feedback.
Develops PAS-004, an oral MEK1/2 inhibitor in early clinical studies for NF1-related tumors and MAPK-driven advanced cancers, while maintaining a discovery-stage schizophrenia program. With no approved products, it funds an outsourced drug-development model through capital raising and potential collaborations.
Develops PAS-004, an oral macrocyclic MEK1/2 inhibitor in early clinical studies for NF1-associated plexiform neurofibromas and MAPK pathway-driven advanced solid tumors. PAS-001, a brain-penetrant small-molecule program intended to down-regulate C4A for schizophrenia, remains at discovery stage; PAS-003 development has ceased.
Operates with a small internal team that manages development while contract research organizations and clinical sites execute trials, and WuXi STA manufactures PAS-004. The cancer study spans U.S., Bulgarian and Romanian sites, while the NF1-PN study includes U.S., Australian and South Korean sites.
Has no approved product or commercialization revenue and relies on equity, debt, collaborations or strategic transactions to fund development. PAS-004 is the only clinical-stage program, and WuXi STA is its only contract manufacturer for drug substance.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Dec 8, 2025 | H.C. Wainwright | Target | $3 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $45.66B · Total debt $0 · Total assets $51.7M · Shareholders' equity $49.84B
- Revenue
- $0
- Operating income
- −$5.7M
- Net income
- −$5.3M
No dividends on record.
| Institutions21 holders · as of Mar 31, 2026 | 38.36% | 12.82M shares | |
| Insiders6 holders · as of Dec 1, 2025 | 1.32% | 442.5K shares | |
| Strategic holders2 holders · as of Jul 1, 2026 | 11.99% | 4.01M shares | |
| Otherremainder | 48.33% | 16.15M shares |
33.41M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Coastlands Capital LPStrategic10 percent owner | 11.48% | 3.84M | 13Gfiled Jul 1, 2026 ↗ |
Adage Capital Partners GP, L.L.C.Institution | 6.28% | 2.10M | 13Fas of Mar 31, 2026 |
Janus Henderson Group PLCInstitution | 6.28% | 2.10M | 13Fas of Mar 31, 2026 |
Squadron Capital Management LLCInstitution | 6.28% | 2.10M | 13Fas of Mar 31, 2026 |
Vivo Capital, LLCInstitution | 6.28% | 2.10M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 17, 2026 | Coastlands Capital LP | 10 percent owner | +100,000 | $0.5300 |
| Nov 28, 2025 | Simon Dumesnil | director | +33,333 | $0.7500 |
| Nov 28, 2025 | Tiago Marques | director, officer: Chief Executive Officer | +33,333 | $0.7500 |
| Nov 28, 2025 | Lawrence Steinman | director | +133,333 | $0.7500 |
- AstraZeneca (ADR)
Approved systemic MEK therapy in adult and pediatric NF1-PN.
- Novartis (ADR)
Mekinist is an approved MEK inhibitor in BRAF-mutant solid tumors.
- Pfizer
Mektovi provides approved MEK inhibition in BRAF-mutant cancers.
- Verastem
Commercial RAF/MEK therapy for RAS/MAPK-driven solid tumors.
- Merck
Koselugo collaboration retains exposure to an approved NF1-PN MEK therapy.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pasithea Therapeutics | $0.5876 | +4.37% | $19.4M | — | — | — | — |
| AstraZeneca (ADR) | $163.56 | +1.18% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Novartis (ADR) | $161.87 | −0.35% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Verastem | $8.01 | −0.12% | $704.7M | — | — | 8.1 | +1,775.4% |
| Merck | $151.84 | +0.13% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Median | 31.4 | 16.3 | 5.6 | +5.1% |